BioSpace News Archive

Biofrontera Inc., a biopharmaceutical company specializing in the commercialization of dermatologic products, reported financial results for the three months ended March 31, 2024 and provided a business update.

Amgen will host a webcasted call for the investment community at 1:00 p.m. PT on Monday, May 20, 2024 following the presentation of new data from TEZSPIRE® in chronic obstructive pulmonary disease at the American Thoracic Society International Conference on May 19 and 20, 2024.

Galapagos NV and Blood Centers of America announced that they have entered into a strategic collaboration for the decentralized manufacturing of Galapagos’ CAR-T cell therapies through BCA’s network in the U.S.

Monte Rosa Therapeutics, Inc. announced that it has commenced an underwritten public offering of its common stock and, in lieu of common stock to certain investors, pre-funded warrants to purchase shares of common stock.

Fortress Biotech, Inc. (Nasdaq: FBIO) (“Fortress”), an innovative biopharmaceutical company focused on acquiring and advancing assets to enhance long-term value for shareholders through product revenue, equity holdings and dividend and royalty revenue, today announced financial results and recent corporate highlights for the first quarter ended March 31, 2024.

Agile Therapeutics, Inc. (Pink: AGRX), a women’s healthcare company, today reported financial results for the three months ended March 31, 2024 and provided a corporate update.

Bruker Corporation announced that its Board of Directors has approved payment of a quarterly cash dividend in the amount of $0.05 per share on the Company’s common stock.

INVO Bioscience, Inc. announced financial results for the first quarter of 2024 and provided a business update.

FibroBiologics, Inc. announced that its 2024 Annual Meeting of Stockholders will take place on August 27, 2024, at 11 a.m. CDT, exclusively through a virtual format.

Cidara Therapeutics, Inc. (Nasdaq: CDTX) (the Company), a biotechnology company using its proprietary Cloudbreak® platform to develop drug-Fc conjugate (DFC) immunotherapies designed to save lives and improve the standard of care for patients facing serious diseases, today reported financial results for the first quarter ended March 31, 2024, and provided an update on its corporate activities and product pipeline.